Key result
Targeted next-generation sequencing identified possible causative non-synonymous mutations in 57.1% (12/21) of patients with dilated cardiomyopathy, including 7 novel mutations.
Observational (n=21)
Targeted next-generation sequencing identified possible causative mutations in 57% of patients with dilated cardiomyopathy, including 7 novel mutations, highlighting its utility for clinical management and family screening.
Requires validation before clinical use in DCM; leaves open pathogenicity and utility of identified variants.
Dilated cardiomyopathy (DCM) is a major cause of sudden cardiac death and heart failure, and it is characterized by genetic and clinical heterogeneity, even for some patients with a very poor clinical prognosis; in the majority of cases, DCM necessitates a heart transplant. Genetic mutations have long been considered to be associated with this disease. At present, mutations in over 50 genes related to DCM have been documented. This study was carried out to elucidate the characteristics of gene mutations in patients with DCM. The candidate genes that may cause DCM include MYBPC3, MYH6, MYH7, LMNA, TNNT2, TNNI3, MYPN, MYL3, TPM1, SCN5A, DES, ACTC1 and RBM20. Using next-generation sequencing (NGS) and subsequent mutation confirmation with traditional capillary Sanger sequencing analysis, possible causative non-synonymous mutations were identified in ~57% (12/21) of patients with DCM. As a result, 7 novel mutations (MYPN, p.E630K; TNNT2, p.G180A; MYH6, p.R1047C; TNNC1, p.D3V; DES, p.R386H; MYBPC3, p.C1124F; and MYL3, p.D126G), 3 variants of uncertain significance (RBM20, p.R1182H; MYH6, p.T1253M; and VCL, p.M209L), and 2 known mutations (MYH7, p.A26V and MYBPC3, p.R160W) were revealed to be associated with DCM. The mutations were most frequently found in the sarcomere (MYH6, MYBPC3, MYH7, TNNC1, TNNT2 and MYL3) and cytoskeletal (MYPN, DES and VCL) genes. As genetic testing is a useful tool in the clinical management of disease, testing for pathogenic mutations is beneficial to the treatment of patients with DCM and may assist in predicting disease risk for their family members before the onset of symptoms.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2015) conducted an observational in Dilated cardiomyopathy (n=21). Targeted next-generation sequencing was evaluated on Identification of possible causative non-synonymous mutations. Targeted next-generation sequencing identified possible causative non-synonymous mutations in 57.1% (12/21) of patients with dilated cardiomyopathy, including 7 novel mutations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: